STOCK TITAN
  1. Home
  2. Sec-filings
  3. HCWB
  4. [S-1/A] HCW Biologics Inc. Amends IPO Registration Statement

HCW Biologics (HCWB) refreshes IPO exhibits in amendment

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
S-1/A

Rhea-AI Filing Summary

HCW Biologics Inc. (HCWB) filed Amendment No. 1 to its Registration Statement on Form S-1 (Registration No. 333-298452). The company states this is an exhibits-only filing, meaning the substantive terms of the underlying registration statement remain unchanged and only the exhibit list and related materials are being updated. The amendment adds or updates various corporate, financing, warrant, equity plan, licensing and debt-related agreements as exhibits, along with legal opinions and Inline XBRL files, while expressly leaving the rest of the registration statement as previously filed.

Positive

  • None.

Negative

  • None.

Filing Explained

The filing does not disclose a completed sale: it describes a proposed offering for after the registration statement becomes effective, while the company is delaying effectiveness until a later amendment or an SEC determination.

Registration Statement Number 333-298452 Form S-1 for HCW Biologics Inc.
Amendment signature date August 28, 2026 Date HCW Biologics Inc. signed Amendment No. 1 to Form S-1
Exchange Act File Number 001-40591 File number referenced for multiple incorporated exhibits
Principal executive office telephone (954) 842-2024 Contact number for HCW Biologics Inc.’s principal executive offices
Registration Statement on Form S-1 regulatory
"HCW Biologics Inc. is filing this Amendment No. 1 to its Registration Statement on Form S-1"
A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.
exhibits-only filing regulatory
"HCW Biologics Inc. is filing this Amendment No. 1 ... as an exhibits-only filing"
Inline XBRL technical
"Inline XBRL Instance Document"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Equity Incentive Plan financial
"2019 Equity Incentive Plan, as amended, and forms of agreement thereunder"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Registration Rights Agreement financial
"Registration Rights Agreement, dated February 20, 2025, between the Company and Square Gate"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
Offering Type shelf

FAQ

What is HCWB filing in Amendment No. 1 to its Form S-1?
HCW Biologics Inc. filed Amendment No. 1 to its Form S-1 as an exhibits-only filing. The amendment updates the exhibit list and related materials, while the remainder of the registration statement is unchanged and therefore omitted from this amendment.

Does this HCWB S-1/A change the terms of the securities offering?
No. HCW Biologics Inc. states that this S-1/A is an exhibits-only filing. It consists of the facing page, explanatory note, Item 16(a), signature pages, and the filed exhibits. The rest of the registration statement, including its previously filed terms, remains unchanged.

When was HCW Biologics Inc. Amendment No. 1 to Form S-1 signed?
The registration statement on Form S-1, Amendment No. 1, was signed on behalf of HCW Biologics Inc. in Miramar, Florida, on August 28, 2026 by Founder & Chief Executive Officer Hing C. Wong, with other directors and the Chief Financial Officer also signing that date.

What kinds of agreements are listed as exhibits in the HCWB S-1/A?
The exhibit index includes warrant forms, equity incentive plans, employment agreements, license and co-development agreements, loan and mortgage agreements, purchase and sale agreements, registration rights agreements, placement agency and lock-up agreements, and related amendments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

S-1 Filings Explained: Reading an IPO Registration →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

As filed with the Securities and Exchange Commission on August 28, 2026

 

Registration No. 333-298452

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Amendment No. 1

to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

HCW BIOLOGICS INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   2834   82-5024477
(State or Other Jurisdiction of   Primary Standard Industrial   (I.R.S. Employer
Incorporation or Organization)   Classification Code Number   Identification Number)

 

2929 N Commerce Parkway

Miramar, FL 33025

(954) 842-2024

Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices

 

Hing C. Wong, Ph.D.

Chief Executive Officer

HCW Biologics Inc.

2929 N Commerce Parkway

Miramar, FL 33025

(954) 842-2024

Name, Address Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service

 

With a copy to:

 

James Groth

Clark Hill PLC

130 E. Randolph St., Ste. 3900

Chicago, IL 60601

(312) 985-5900

  

Yevgeniya (Jeny) Zarmon

Clark Hill PLC

210 Carnegie Center, Suite 102

Princeton, NJ 08540

(609) 785-2918

 

Approximate Date of Commencement of Proposed Sale to the Public: From time to time after the effective date of this registration statement, as determined by market conditions.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) of the Securities Act, may determine.

 

 

 

 

 

 

EXPLANATORY NOTE

 

HCW Biologics Inc. is filing this Amendment No. 1 to its Registration Statement on Form S-1 (File No. 333-298452) as an exhibits-only filing. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

 

 

 

 

PART II

 

Item 16. Exhibits.

 

EXHIBIT INDEX

 

        Incorporated by reference   Filed or
Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date   furnished herewith
3.1   Amended and Restated Certificate of Incorporation   8-K   001-40591   3.1   07/26/2021    
3.1a   Certificate of Amendment of Certificate of Incorporation, filed March 31, 2025   8-K   001-40591   3.1a   04/01/2025    
3.1b   Certificate of Correction of the Certificate of Amendment of Certificate of Incorporation, filed April 1, 2025   8-K   001-40591   3.1b   04/01/2025    
3.2   Amended and Restated Bylaws   8-K   001-40591   3.2   07/26/2021    
4.1   Specimen Stock Certificate   S-1/A   333-256510   4.1   07/09/2021    
4.2   Description of Securities   10-K   001-40591   4.2   03/29/2022    
4.3   Form of New Warrant   8-K   001-40591   4.1   11/20/2025    
4.4   Form of Common Stock Purchase Warrant   8-K   001-40591   4.1   02/19/2026    
4.5   Form of Pre-Funded Common Stock Purchase Warrant   8-K   001-40591   4.2   02/19/2026    
4.6   Form of Common Stock Warrant, dated May 7, 2025, between Company and Holder   10-Q   001-40591   10.13   08/18/2025    
4.7   Form of Pre-Funded Common Stock Purchase Warrant   8-K   001-40591   4.1   5/21/2026    
4.8   Form of Common Stock Purchase Warrant   8-K   001-40591   4.2   5/21/2026    
5.1   Opinion of Clark Hill PLC                   X
10.1   Form of Inducement Agreement between the Company and Armistice Capital Management LLC   8-K   001-40591   10.1   11/20/2025    
10.2   Securities Purchase Agreement, dated February 17, 2026, between Company and Purchaser   8-K   001-40591   10.2   02/19/2026    
10.3   Amendment to Existing Warrants Agreement, dated February 17, 2026, between the Company and Purchaser   8-K   001-40591   10.3   02/19/2026    
10.4   Form of Lock-up Agreement   S-1   333-393396   10.42   02/11/2026    
10.5   Form of Indemnification Agreement between HCW Biologics Inc. and each of its officers and directors.   S-1/A   333-256510   10.1   07/09/2021    
10.6+   2019 Equity Incentive Plan, as amended, and forms of agreement thereunder.   S-1/A   333-256510   10.2   07/09/2021    
10.7+   First Amendment to 2019 Equity Incentive Plan.   S-1/A   333-256510   10.3   07/09/2021    
10.8+   2021 Equity Incentive Plan and forms of agreement thereunder   S-1/A   333-256510   10.4   07/09/2021    
10.9+   Employment Agreement, dated July 6, 2021, between Peter Rhode and HCW Biologics Inc.   S-1/A   333-256510   10.6   07/09/2021    
10.10+   Employment Agreement, dated October 9, 2019, between Rebecca Byam and HCW Biologics Inc.   S-1/A   333-256510   10.7   07/09/2021    

 

II-1

 

 

       

Incorporated by reference

  

Filed or

furnished

herewith

Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date  
10.11+   Non-Employee Director Compensation Policy.   S-1/A   333-256510   10.8   07/09/2021    
10.12+   Employment Agreement, dated August 28, 2021, between Dr. Hing C. Wong and HCW Biologics Inc.   S-1/A   333-256510   10.13   07/09/2021    
10.13+   Executive Incentive Bonus Plan   S-1/A   333-256510   10.11   07/09/2021    
10.14†   Exclusive License Agreement, dated December 24, 2020, between HCW Biologics Inc. and Wugen, Inc.   S-1/A   333-256510   10.10   07/09/2021    
10.15†   Master Services Agreement, dated March 14, 2019, between HCW Biologics Inc. and EirGenix, Inc.   S-1/A   333-256510   10.12   07/09/2021    
10.16†#   Purchase and Sale Agreement, by and between HCW Biologics Inc. and Wai 3300 Corporate Way, LLC, dated May 27, 2022   10-Q   001-40591   10.1   08/12/2022    
10.17#   Loan Agreement by and between HCW Biologics Inc. and Cogent Bank, dated August 15, 2022   10-Q   001-40591   10.1   11/07/2022    
10.18#   Mortgage and Security Agreement by and between HCW Biologics Inc. and Cogent Bank, dated August 15, 2022   10-Q   001-40591   10.2   11/07/2022    
10.19   Form of Subscription Agreement, dated February 20, 2024, by and between the Company and the Subscribers party thereto   8-K   001-40591   10.1   02/22/2024    
10.20   Form of Amended and Restated Senior Secured Note Purchase Agreement, dated July 2, 2024, by and between the Company and the Purchase party thereto   10-Q   001-40591   10.1   08/14/2024    
10.21   Form of Amended and Restated Pledge Agreement, dated July 2, 2024, by and among the Company, Escrow Agent and Noteholder parties thereto   10-Q   001-40591   10.3   08/14/2024    
10.22   Form of Escrow Agreement, dated May 1, 2025, by and between the Company, Escrow Agent and Noteholder party thereto   10-Q   001-40591   10.4   08/14/2024    
10.23   Form of First Amendment to Amended and Restated Secured Note Purchase Agreement, dated September 30, 2024, by and between the Company and Purchaser party thereto   10-Q   001-40591   10.5   11/14/2024    
10.24   Form of Secured Promissory Note by and between the Company and the Holder party thereof   10-Q   001-40591   10.2   08/14/2024    
10.25   Second Amendment to Amended and Restated Senior Secured Note Purchase Agreement and Related Agreements, dated May 1, 2025, between Company and Holder   10-Q   001-40591   10.12   08/18/2025    
10.26   Equity Purchase Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4.   8-K   001-40591   10.1   2/21/2025    
10.27   Registration Rights Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4   8-K   001-40591   10.2   2/21/2025    
10.28   First Amendment to the Equity Purchase Agreement, dated August 14, 2025, between the Company and Square Gate Master Fund - Series 4.   8-K   001-40591   10.1   08/15/2025    

 

II-2

 

 

       

Incorporated by reference

  

Filed or

furnished

herewith

Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date  
10.29   Amended and Restated Amended and Restated License, Research and Co-Development Agreement, dated November 17, 2025, between the Company and Beijing Trimmune Biotech Co., Ltd.   S-1   333-293396   10.40   02/11/2026    
10.30†#   Amendment 1 to Amended and Restated License, Research and Co-Development Agreement, dated January 27, 2026, between the Company and Beijing Trimmune Biotech Co., Ltd.   S-1   333-293396   10.43   02/11/2026    
10.31†#   Shareholder Purchase Agreement, dated October 10, 2025, between co-founders of Beijing Trimmune Biotech Co., Ltd., including the Company   S-1   333-293396   10.44   02/11/2026    
10.32   Exclusive License Agreement 12-Month Suspension, dated May 29, 2025, between the Company and Wugen, Inc.   10-Q   001-40591   10.17   08/18/2025    
10.33   Settlement Agreement and Release, dated July 13, 2024, by and between the Company and Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc.   10-Q   001-40591   10.6   11/14/2024    
10.34   Placement Agency Agreement, dated February 17, 2026, between the Company and Maxim Group LLC   8-K   001-40591   10.1   02/19/2026    
10.35   Form of Securities Purchase Agreement   8-K   001-40591   10.1   5/21/2026    
10.36   Form of Registration Rights Agreement by and between the Company and the Investors   8-K   001-40591   10.2   5/21/2026    
10.37   Form of Placement Agency Agreement, by and between the Company and E.F. Hutton & Co. LLC   8-K   001-40591   10.3   5/21/2026    
10.38*   Form of Lock-Up Agreement                    
23.1*   Consent of Independent Registered Public Accounting Firm                    
23.2   Opinion of Clark Hill PLC (included in Exhibit 5.1)                   X
101.INS   Inline XBRL Instance Document                   X
101.SCH   Inline XBRL Taxonomy Extension Schema Document                   X
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                   X
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document                   X
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document                   X
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                   X
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)                   X
107*   Filing Fee Table                    

 

+ Indicates a management contract or compensatory plan or arrangement.

 

†† Certain information in this document has been excluded pursuant to Item 601(b)(10) of Regulation S-K. Such excluded information is not material and is the type of information the Registrant treats as private and confidential. The Registrant agrees to furnish supplementally such information to the SEC upon request.

 

# Certain information in this document has been excluded pursuant to Item 601(a)(5) or (a)(6) of Regulation S-K. The Registrant agrees to furnish supplementally such information to the SEC upon request.

 

* Previously filed.

 

II-3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, in the city of Miramar, State of Florida, on August 28, 2026.

 

  HCW BIOLOGICS INC.
     
  By: /s/ Hing C. Wong
  Name: Hing C. Wong
  Title: Founder & Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Signature   Title   Date
         

*

Scott T. Garrett

   Chairman of the Board of Directors   August 28, 2026
         

*

Rebecca Byam

   Chief Financial Officer   August 28, 2026
         

*

Hing C. Wong

   Chief Executive Officer   August 28, 2026
         

*

Rick S. Greene

   Director   August 28, 2026
         

*

Lisa M. Giles

   Director   August 28, 2026

 

By: /s/ Hing C. Wong  
  Hing C. Wong, Attorney-in-Fact  

 

II-4

 

Source: View Original Filing on SEC EDGAR